RPRX
Royalty Pharma plc Healthcare - Pharmaceutical Royalties Investor Relations →
Royalty Pharma plc (RPRX) closed at $45.36 as of 2026-03-20, trading 40.7% above its 200-week moving average of $32.24. The stock is currently moving closer to the line, down from 41.8% last week. With a 14-week RSI of 81, RPRX is in overbought territory.
Trading volume is running at 1.6x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.06 ratio) is neutral — neither side is clearly dominating.
Over the past 252 weeks of data, RPRX has crossed below its 200-week moving average 6 times. On average, these episodes lasted 29 weeks. The average one-year return after crossing below was -13.1%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $26.2 billion, RPRX is a large-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at 13.2%. The stock trades at 3.0x book value.
Over the past 4.9 years, a hypothetical investment of $100 in RPRX would have grown to $112, compared to $165 for the S&P 500. RPRX has returned 2.4% annualized vs 10.8% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: RPRX vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After RPRX Crosses Below the Line?
Across 6 historical episodes, buying RPRX when it crossed below its 200-week moving average produced an average return of -5.2% after 12 months (median -9.0%), compared to +9.7% for the S&P 500 over the same periods. 33% of those episodes were profitable after one year. After 24 months, the average return was -26.8% vs +33.0% for the index.
Each line shows $100 invested at the moment RPRX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
RPRX has crossed below its 200-week MA 6 times with an average 1-year return of +-13.1% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| May 2021 | May 2021 | 1 | 7.9% | +4.7% | +26.6% |
| Jun 2021 | Apr 2022 | 41 | 16.3% | +3.3% | +19.3% |
| May 2022 | Jun 2022 | 7 | 4.3% | -10.0% | +26.2% |
| Sep 2022 | Oct 2022 | 5 | 2.3% | -33.2% | +23.2% |
| Dec 2022 | Feb 2025 | 114 | 32.0% | -30.2% | +23.0% |
| Mar 2025 | Apr 2025 | 5 | 4.6% | N/A | +48.0% |
| Average | 29 | — | +-13.1% | — |
Frequently Asked Questions
Is RPRX below its 200-week moving average?
No. Royalty Pharma plc (RPRX) is currently 40.7% above its 200-week moving average of $32.24. It would need to fall to $32.24 to cross below the line.
What is RPRX's 200-week moving average price?
Royalty Pharma plc's 200-week moving average is $32.24 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when RPRX drops below its 200-week moving average?
RPRX has crossed below its 200-week moving average 6 times in our data. The average one-year return after these crossings was -13.1%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 29 weeks on average.
Is RPRX a good value right now?
Here's what our data says about RPRX as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 81 (overbought). Free cash flow is currently negative. Return on equity is 13.2%. Price-to-book is 3.0x. This is not a buy or sell recommendation — always do your own research.
How does RPRX compare to the S&P 500?
Over the past 4.9 years, $100 invested in RPRX would have grown to $112, compared to $165 for the S&P 500. That's 2.4% annualized vs 10.8% for the index. RPRX has underperformed the broader market over this period.
Does RPRX pay a dividend?
Yes. Royalty Pharma plc currently pays a dividend yield of 207.00%.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20